BeStock  
Stocks › Biotechnology › ASND

Ascendis Pharma A/S ASND

US equityMarket cap rank #1027Biotechnology
$252.73 −$3.23 (-1.26%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $252.73 0.00%
Open$255.44
Prev close$255.96
Day range$251.55 – $256.65
Volume602.9K
Market cap$16.63B
P/E (TTM)34.7
Dividend yield–

ASND Stock News

Headlines matching Ascendis Pharma A/S or the ASND ticker, most recent first.

  • Barclays Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $329Market news · 30 Sep 2026 · Direct mention
  • Oppenheimer Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $312 PositiveMarket news · 3 Sep 2026 · Direct mention
  • Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $273Market news · 28 Sep 2026 · Direct mention
  • A Quick Look at Today's Ratings for Ascendis Pharma A/S(ASND.US), With a Forecast Between $273 to $344Market news · 2 Sep 2026 · Direct mention
  • Wedbush Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $327Market news · 17 Sep 2026 · Direct mention
  • A Quick Look at Today's Ratings for Ascendis Pharma A/S(ASND.US), With a Forecast Between $304 to $344Market news · 16 Sep 2026 · Direct mention
  • Raymond James Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $287 PositiveMarket news · 15 Sep 2026 · Direct mention
  • H.C. Wainwright Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $344Market news · 10 Sep 2026 · Direct mention
  • Evercore Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $329Market news · 8 Aug 2026 · Direct mention
  • Cantor Fitzgerald Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $300Market news · 8 Aug 2026 · Direct mention
  • Barclays Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $345Market news · 7 Aug 2026 · Direct mention
  • H.C. Wainwright Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Cuts Target Price to $344 NegativeMarket news · 31 Aug 2026 · Direct mention
  • Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $275Market news · 31 Aug 2026 · Direct mention
  • H.C. Wainwright Initiates Ascendis Pharma A/S(ASND.US) With Buy Rating, Announces Target Price $345Market news · 27 Aug 2026 · Direct mention
  • J.P. Morgan Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Announces Target Price $300Market news · 20 Aug 2026 · Direct mention

Discussion

No comments yet — be the first to weigh in on ASND.

Sign in to join the discussion.

Scroll to Top